Looks like besides the mess, something is about to happen. Welcome to mtp daily. I am chuck todd. What could be a pivotal day for u. S. Withdrawal from afghanistan. We expect to hear from President Biden this afternoon with an update on the situation. All of this comes as we confirm the president decided against extending the August 31st deadline, despite pleas from our allies and Intel Community and a lot of folks on the ground in the capitol as u. S. Forces scramble to evacuate american Staff And Family and now we know that afghans, the taliban plan to stay in the way of afghans getting to the airport. More on this in a moment. The president met with the national Security Team and g7 leaders. He was supposed to deliver remarks on afghanistan at noon. Taliban spokesman said the u. S. Must complete evacuation by August 31st, a peek from today, period. Signaling afghans will no longer be allowed to leave the country. Evacuations through kabul are continuing, at a brisk pace, more than 2
Infection. Next slide. Now, if you look at the people who should benefit from this, this is a list from the fda and the Nih Treatment guidelines about all of the people who may have significant benefit from this type of therapy if given early in their infection. Im not going to go through each and every one of them, but as you can see, there are a number of conditions on this slide that could benefit from the monoclonal Antibody Treatment after infection. Theres also the benefit of prevention using Monoclonal Antibodies. We know now that the fda just a couple of weeks ago authorized the regeneron Monoclonal Antibody for post exposure, namely for the prevention of covid19 after someone has been exposed to a documented case. There are now studies in preexposure prophylactic. The treatment Guidelines Panel will give you all the information and its accessible on the website shown here. For physicians, patients and others who want to know how you can get Monoclonal Antibodies administered,
Sars-covi-2. so you can do an indication for these antibodies that are twofold. in this regard clinical trials have demonstrated that early treatment with monoclonal antibodies can reduce the risk of covid-19 hospitalization or death by 70 to 85%. it is important to emphasize that this must be done early in infections and not wait, of course, until a person is sick enough to be hospitalized. that s when you get the best effect. we want people out there including physicians as well as potential patients to realize the advantage of this very effective way of treating early